"Eli Lilly & Co.’s Strattera faces generic competition after the drugmaker lost a U.S. court case over the attention-deficit treatment, its second patent ruling setback in a month." The ruling means Lilly expects "'near-term entry' of generic versions" and has reduced its sales forecast. Lilly will appeal the ruling. Bloomberg News (8/13, Decker) reported the ruling "favors generic-drug companies including Teva Pharmaceutical Industries Ltd. and Novartis AG's Sandoz unit."
